Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin PK in Critical Care Patients
NCT02142075Phase 3Completed
- Sponsor
- CHU de Poitiers
- Start
- Mar 2014
- Primary completion
- Sep 2015
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of daptomycin in Bacteremia, infective endocarditis (IE), skin and soft tissue infection (SSTI), sponsored by CHU de Poitiers. Started Mar 2014; status: completed.
02
Drugs
daptomycin
03
Conditions
Bacteremiainfective endocarditis (IE)skin and soft tissue infection (SSTI)
Beyond the preview
Go deeper on NCT02142075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142075.